Endocrine Abstracts

Neuroendocrine tumors (NETs) represent a very heterogenous group of neoplasms, comprising approximately 2% of all malignant tumors of gastroenteropancreatic system. Although they are characterized by a relatively slow tumor growth, they have a malignant potential and, in fact, most of them are diagnosed when distant metastases have been developed. NETs, when functioning, are causing symptoms related not only to the tumour mass itself, but also to the specific hormonal peptide ...

Introduction: Glucagonomas are rare functional pancreatic neuroendocrine tumours (p NETs), with an annual occurrence of 0.01 to 0.1 new cases per 100,000. Objective: We focused on presenting symptoms, primary’s size and location, presence of metastases, biomarkers at diagnosis, histology, response to first line treatment (clinical and biochemical), disease fee survival (DFS) and PFS (progression free survival). Methods: Eighteen pa...

Background: 177Lu-DOTATATE is increasingly used in patients with advanced neuroendocrine tumour (NET). However, few circulating biomarkers are available to predict progression-free survival (PFS) of patients received 177Lu-DOTATATE.Materials and methods: Clinicopathological data and data of baseline circulating biomarkers including neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), e...

Background: The incidence of neuroendocrine neoplasms (NENs) in younger populations (<50 years) is increasing and was 1.8 per 100,000 persons in 2011. There is limited data on NENs and pregnancy.Methods: A retrospective analysis was performed on pregnant women with NENs managed in an ENETS Centre of Excellence. The objectives of the study were to describe the tumour characteristics, pregnancy outcomes, treatment and the tumour behaviour intra-pregnan...

Introduction: High doses/frequency of somatostatin analogues (SSA) are often used to control refractory functional symptoms and/or tumour progression in patients treated with standard doses of SSAs, but there is limited evidence for the efficacy of this strategy.Methods: Retrospective analysis of 47 NET patients on lanreotide Autogel 120 mg every 3 weeks (as monotherapy). Progression-free survival (PFS) and clinical outcomes were assessed. A 30% change i...

Introduction: Escalated doses of octreotide LAR are commonly used to control functional symptoms and/or tumour growth, but there is limited evidence regarding the efficacy of this approach.Methods: Retrospective analysis of 69 NET patients treated with octreotide LAR 30 mg every 3 weeks (as monotherapy). Progression-free survival (PFS) and clinical outcomes were assessed. A 30% change in symptomatology and biomarker levels was considered significant....

Background: Gastric neuroendocrine tumours (g-NETs) constitute about 7% of digestive NETs, with type 1 g-NETs, linked to chronic atrophic gastritis, accounting for 80% of cases. These tumours are generally small, low-grade, and exhibit excellent long-term survival rates. Increased endoscopy and awareness have raised their incidence, prompting interest in management strategies. Current guidelines recommend either endoscopic surveillance or resection for type 1 g-NETs <10 mm...

Background: Rectal neuroendocrine tumours (r-NETs) are the second most common neuroendocrine tumours in the digestive tract, with increasing incidence due to improved colonoscopy and cancer screening. These small, yellowish, low-grade lesions are often found incidentally during colonoscopies and generally have a favourable prognosis, with median survival sometimes exceeding 30 years. However, up to 20% of r-NETs may be misdiagnosed during endoscopy, risking inadequate treatmen...

Background: Bone metastases have been described in up to 15% of patients with NETs and are associated with a worse clinical outcome. Here we investigate the role of CTCs as a marker of bone metastases in a large cohort of patients with gastroenteropancreatic NETs.Methods: To be eligible for the study, patients were required to be ≥ 18 years old, have histologically confirmed midgut or pancreatic NET (pNET) and metastatic disease measurable by RECIS...

Background: Gastrointestinal (GI) neuroendocrine tumours (NETs) are potentially malignant lesions originating from the enterochromaffin cells of the GI tract. These neoplasms often produce characteristic hormonal syndromes and can cause debilitating symptoms. Endoscopic submucosal dissection (ESD) is a well-established, complex, endoscopic technique, which allows for full resection of the mucosal and submucosal lesions without the need for open surgery.M...